BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

How to Apply for the Rubicon Research IPO: Step-by-Step Investment Guide

 

Rubicon Research Limited, incorporated in 1999, is a pharmaceutical company engaged in the development, manufacturing, and commercialisation of differentiated formulations. The company has built a portfolio of products approved by the US FDA, with a significant portion already commercialised in the US generic pharmaceutical market. Beyond the US, Rubicon has filed and registered products in several international markets, including the UK, Australia, Singapore, Saudi Arabia, and the UAE. The company also provides contract manufacturing services in select regions, supported by its manufacturing and R&D facilities in India and Canada. Its market position is strengthened by a diverse customer base, including major wholesalers, pharmacy chains, and managed care organisations.

Investors can apply for the Rubicon Research IPO through both online and offline channels. Online applications can be made via the ASBA (Application Supported by Blocked Amount) facility through net banking or UPI, using the investor’s demat account. Offline applications involve submitting a physical form along with payment instructions to the designated banks or brokers. Investors should ensure they meet the minimum subscription requirements and double-check their personal and demat details before submitting the application. Following allotment, shares will be credited directly to the demat account, and any unallotted funds will be released.

For more details, visit the Rubicon Research IPO page.

Rubicon Research IPO Details and Objectives

Details

Information

IPO Date

October 9, 2025 to October 13, 2025

Issue Size

2,84,02,040 shares

(aggregating up to ₹1,377.50 Cr)

Price Band

₹461 to ₹485 per share

Lot Size

30 shares

Listing At

BSE NSE

Purpose of the IPO

  • Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company

  • Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes

Timeline of Rubicon Research IPO

Event

Date

IPO Open Date

Thu, Oct 9, 2025

IPO Close Date

Mon, Oct 13, 2025

Tentative Allotment

Tue, Oct 14, 2025

Initiation of Refunds

Wed, Oct 15, 2025

Credit of Shares to Demat

Wed, Oct 15, 2025

Tentative Listing Date

Thu, Oct 16, 2025

Cut-off time for UPI mandate confirmation

5 PM on Mon, Oct 13, 2025

Pricing & Lot Size of Rubicon Research IPO

Price Band for the IPO

  •  ₹461 to ₹485 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Retail (Min)

1

30

₹14,550

Retail (Max)

13

390

₹1,89,150

S-HNI (Min)

14

420

₹2,03,700

S-HNI (Max)

68

2,040

₹9,89,400

B-HNI (Min)

69

2,070

₹10,03,950

Rubicon Research IPO Application Process

The Rubicon Research IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

Step 1: Login to Your Trading Platform

Access your trading account using the broker's app or website.

Step 2: Navigate to the IPO Section

Go to the IPO section to view active IPO listings.

Step 3: Select the Open IPO and Click Apply

Locate Rubicon Research IPO in the list of available IPOs and click the ‘Apply’ button.

Step 4: Enter the Quantity of Shares You Wish to Apply For

Specify the number of shares (minimum lot size: 30 shares) within the price band of ₹461 to ₹485 per share.

Step 5: Provide Your UPI ID

Enter your UPI ID for payment authorization and ensure sufficient funds in your bank account.

Step 6: Confirm the Application

Review your application details and confirm the UPI mandate before 5 PM on the last application day.

Step 7: Complete the Process and Wait for Allotment

Submit the application and monitor the allotment status to check if shares have been allocated to you.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹749.70 crore in FY23 to ₹1,647.60 crore as of June 2025.

  • Total income: Reached ₹356.95 crore in FY25.

  • Profit After Tax (PAT): Stood at ₹43.30 crore for June 2025.

  • Net Worth: Recorded at ₹593.67 crore in FY25.

  • Reserves and Surplus: Recorded at ₹397.50 crore (June 2025), growing steadily over the years.

  • EBITDA: Stood at ₹79.74 crore in June 2025.

Recent Performance and Growth Prospects

  • The company has demonstrated steady growth in its overall asset base over the recent years.

  • Total income has shown consistent improvement, reflecting expanding business operations and market presence.

  • Profitability has remained positive, indicating effective cost management and operational efficiency.

  • Net worth has increased steadily, highlighting the company’s strengthening financial position.

  • Reserves and surplus have grown over time, providing additional financial stability and support for future initiatives.

  • Operational performance, as reflected in EBITDA, suggests the company is maintaining stable earnings before interest, taxes, depreciation, and amortisation.

  • Overall, the company’s recent financial trends indicate a foundation for continued growth and expansion in domestic and international markets.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company’s reliance on approvals from regulatory authorities, such as the US FDA, may lead to delays or uncertainties in product launches.

  • A significant portion of revenue comes from a few major customers and wholesalers, creating potential exposure to changes in demand or contractual terms.

Opportunities and Growth Potential

  • Expansion into international markets, including the UK, Australia, Singapore, Saudi Arabia, and the UAE, offers potential for diversified revenue streams.

  • Ongoing product development, a steady pipeline of new formulations, and contract manufacturing services provide avenues for operational growth and market presence.

Key Performance Indicator (KPI)

KPI

Values

ROE

29.02%

ROCE

26.45%

Debt/Equity

0.73

RoNW

29.02%

PAT Margin

10.37%

EBITDA Margin

20.67%

Rubicon Research IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

MUFG Intime India Pvt.Ltd.

Axis Capital Ltd.

Company Address of Rubicon Research Ltd

Rubicon Research Ltd. MedOne House, B-75, Road No. 33, Wagle Estate, Thane, Maharashtra, 400604

Phone: 022 61414000

Email: investors@rubicon.co.in

Website: https://www.rubicon.co.in/

Conclusion

Rubicon Research Limited operates as a pharmaceutical company with a presence in both domestic and international markets. Its business involves the development, manufacturing, and commercialisation of differentiated formulations, supported by regulatory approvals and a network of customers and distributors. The company maintains manufacturing and R&D facilities in multiple locations, which contribute to its ongoing operations and product development efforts.

The IPO application can be completed through online or offline channels, with steps involving selection of the IPO, submission of application details, and confirmation of payment through UPI or designated banks. Following the allotment process, shares are credited to the applicant’s demat account, and unallotted funds are returned.

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Rubicon Research IPO allotment status.

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|